Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
NCT05777603
Recruiting
Background: Non-small cell lung cancer (NSCLC) can be hard to treat and is often fatal. People with NSCLC commonly have changes in the bacteria that populate their lungs. These bacterial changes may aid tumor growth. Researchers want to find out if treating the bacteria, too, can help cancer treatment work better. Objective: To test 2 inhaled antibiotics (aztreonam and vancomycin), combined with a standard cancer treatment, in people with NSCLC. Eligibility: People aged 18 years and older w... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
12/01/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Advanced Non Small Cell Lung Cancer
Register for Updates
Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders
NCT05726591
Recruiting
Background: People with cerebral palsy, spina bifida, muscular dystrophy, or spinal cord injury often have muscle weakness and problems controlling how their legs move. This can affect how they walk. The NIH has designed a robotic device (exoskeleton) that can be worn on the legs while walking. The wearable robot offers a new form of gait training. Objective: To learn whether a robotic device worn on the legs can improve walking ability in those with a gait disorder. Eligibility: People age... Read More
Gender:
All
Ages:
Between 3 years and 17 years
Trial Updated:
12/01/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cerebral Palsy, Muscular Dystrophy, Spina Bifida, Incomplete Spinal Cord Injury
Register for Updates
Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
NCT05715281
Recruiting
This phase II trial tests how well atezolizumab works in combination with tiragolumab in treating patients with rare solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced stage). Immunotherapy with monoclonal antibodies, such as atezolizumab and tiragolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The study biopsy takes small pieces of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland
Conditions: Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm
Register for Updates
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
NCT05705401
Recruiting
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Gender:
All
Ages:
40 years and above
Trial Updated:
12/01/2023
Locations: Greater Baltimore Medical Center, Baltimore, Maryland
Conditions: HER2-positive Breast Cancer
Register for Updates
Resiniferatoxin for the Management of Refractory Morton s Neuroma Pain
NCT05695339
Recruiting
Morton s neuroma is an irritation of the nerves that affect the feet. People with this condition may have burning or shooting pain in the balls of their feet. They may also have numbness in adjacent areas. These symptoms may become more frequent and severe over time. The pain may become permanent. Current treatments tend to be short-lived, and they do not work in all people. Better treatments are needed. Objective: To test a study drug, resiniferatoxin (RTX), in people with Morton s neuroma.... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Morton's Neuroma
Register for Updates
Individual Variations of Taste and Smell Perception in Alcohol Use Disorder (AUD)
NCT05677321
Recruiting
Background: Alcohol use disorder (AUD) is the most common substance use disorder in the world. Long-term AUD can affect a person s sense of taste and smell. This natural history study will compare alcohol drinking behaviors and measures of taste and smell in people with and without AUD. Objective: To understand how alcohol use changes the senses of taste and smell. Eligibility: People aged 18 to 65 years with or without AUD. Design: Participants will be screened. They will have several te... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
12/01/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Alcohol Use Disorder
Register for Updates
Imaging Characterization of the Biomechanical Coupling of Brain and Skull
NCT05675423
Recruiting
Background: Traumatic brain injury (TBI) affects over 1.7 million people in the United States each year. Many cases are mild, but people with a history of TBI may have long-term symptoms; they are also known to be more susceptible to future concussions. Researchers are working to understand how TBI affects tissues in and around the brain over the long term. This natural history study will investigate how a TBI may change the stiffness of the brain and its surrounding connective tissues. Object... Read More
Gender:
All
Ages:
Between 21 years and 65 years
Trial Updated:
12/01/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Traumatic Brain Injury (Tbi), Traumatic Meningeal Enhancement (Tme)
Register for Updates
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies
NCT05665530
Recruiting
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of PRT2527 as a monotherapy and in combination with zanubrutinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: American Oncology Partners of Maryland, PA, Bethesda, Maryland
Conditions: Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma
Register for Updates
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
NCT05665361
Recruiting
Background: Kidney cancer is the 12th leading cause of cancer-related death in the United States. Some kidney tumors do not respond well to current treatments. Better treatments are needed. Objective: To test a pair of drugs (sasanlimab and palbociclib) in people with kidney cancers. Eligibility: People aged 18 years and older with kidney cancer; specifically, clear cell renal cell carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC). Design: Participants will be screened. They will... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc)
Register for Updates
A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia
NCT05663320
Recruiting
Background: Children with congenital adrenal hyperplasia (CAH) can survive well into adulthood with proper treatment. But the change from pediatric to adult care can be challenging. Many people with CAH need extra support as they learn to take control of their own health care needs. Researchers have studied how people respond to different types of patient education. Now researchers want to find out if virtual education, via computer, is a good way to teach people how to manage CAH as they becom... Read More
Gender:
All
Ages:
Between 16 years and 22 years
Trial Updated:
12/01/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Congenital Adrenal Hyperplasia
Register for Updates
Observational Study of Advanced Data Analytics in Genetic Conditions
NCT05657405
Recruiting
Background: The genes a person is born with can sometimes cause serious diseases. Genetic diseases are rare, but they can have a big impact on the people they affect. Researchers have already made great strides in understanding how some genes cause disease. But they would like to have even better tools to analyze and understand genetic data. To create these new tools, they need to gather health and genetic data from a lot of people. Objective: This natural history study will gather medical in... Read More
Gender:
All
Ages:
Between 1 day and 120 years
Trial Updated:
12/01/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Genetic Conditions
Register for Updates
Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers
NCT05652478
Recruiting
Background: People with HIV take drugs to keep the amount of virus in their body low. One type of these drugs, called integrase strand transfer inhibitors (INSTIs), can cause weight gain over time. Weight gain can cause diabetes, heart disease, and other serious issues. Researchers want to understand how INSTIs cause weight changes. Objective: To see how a common INSTI, dolutegravir (DTG), affects how the body uses energy. DTG will be compared with a non-INSTI drug, tenofovir alafenamide (TAF... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
12/01/2023
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metabolic Effects, Weight Gain, HIV, Integrase Strand Transfer Inhibitors
Register for Updates